Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.

Abstract

Lipids disorder is the principal cause of atherosclerosis and may present with several forms, according to blood lipoprotein prevalence. One of the most common forms is combined dyslipidemia, characterized by high levels of triglycerides and low level of high-density lipoprotein. Single lipid-lowering drugs may have very selective effect on lipoproteins; hence, the need to use multiple therapy against dyslipidemia. However, the risk of toxicity is a concerning issue. In this review, the effect and safety of an approved combination therapy with simvastatin plus fenofibrate are described, with an analysis of pros and cons resulting from randomized multicenter trials, meta-analyses, animal models, and case reports as well.

• Authors: Nicola Tarantino, Francesco Santoro, Luisa De Gennaro, Michele Correale, Francesca Guastafierro, Antonio Gaglione, Matteo Di Biase, Natale Daniele Brunetti
• Journal: Vascular health and risk management (Vasc Health Risk Manag) Vol. 13 Pg. 29-41 ( 2017) ISSN: 1178-2048 [Electronic] New Zealand
• PMID: 28243111 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers
• Drug Combinations
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipoproteins, HDL
• Triglycerides
• Simvastatin
• Fenofibrate

Topics

• Animals
• Biomarkers (blood)
• Drug Combinations
• Dyslipidemias (blood, diagnosis, drug therapy)
• Fenofibrate (administration & dosage, adverse effects)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage, adverse effects)
• Lipoproteins, HDL (blood)
• Simvastatin (administration & dosage, adverse effects)
• Treatment Outcome
• Triglycerides (blood)